Sumitomo Dainippon Pharma Co Ltd and Roivant Sciences Ltd Memorandum of Understanding for Strategic Alliance Call Transcript
This is Nomura speaking. Thank you for joining the call. I will go over the presentation to explain the Memorandum of Understanding for our Strategic Alliance with Roivant Sciences.
Please go to Slide 3. This is the overview. We entered into MOU with respect to stock acquisition for select Roivant subsidiaries, equity investment in Roivant and acquisition of technology platforms. You can find more details on the slide.
With regard to stock acquisition of subsidiaries, Sumitomo will acquire Roivant's interest in 5 of its subsidiaries. And as for obtaining options, Sumitomo will obtain options to acquire Roivant's interests in 6 additional subsidiaries. These 11 companies, subject to stock acquisition or option agreement, collectively have over 25 innovative clinical programs. In respect to acquisition of platforms and cooperation, Sumitomo will acquire Roivant's pharma-related technology platform such as DrugOme and Digital Innovation, on which I will explain later, and data technology talent.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
